HeartWare dives on big Q1 sales, earnings misses
Shares prices for HeartWare International (NSDQ:HTWR) plunged this morning after the implantable heart pump maker posted 1st-quarter earnings that badly missed expectations on Wall Street. Framingham, Mass.-based HeartWare reported that losses widened 20.1% to -$17.5 million, or -$1 per share, on a -21.3% revenue slide to $55.1 million. Adjusted to exclude 1-time items, losses per share were -95¢, -16¢ off the forecast on The Street, where analysts were looking for sales of $59.9 million. “In the 1st quarter, our international revenue performance was impacted by competitive dynamics in Germany, as well as lower implant volumes in certain other international markets,” president &CEO Doug Godshall said in prepared remarks. “In the U.S., the bridge-to-transplant segment of the market for which the HVAD system is approved, showed softness resulting from a slowdown in the volume of patients eligible for bridge-to-transplant procedures at the start of the year and an evolving trend toward destination therapy due to ease of reimbursement. Our 1st-quarter financial performance and the overall market dynamics reinforce the importance of our work toward securing a DT indication in the U.S. and focusing our energies upon the continued enhancement of our technologies. “Despite 1st-quarter trends, the HVAD system remains the most versatile pump, utilized in the widest range of patients, among currently available ventricular as...
650,000 renal, hepatic, and cardiothoracic (heart and/or lung) transplants have been performed in the U.S. since 1988, with UNOS reporting a 20% increase in transplants between 2012 through 2016. The immunosuppression vital to maintaining graft survival comes with a 65-200X greater frequency of SCC compared to the non-transplant population. These SCC exhibit more aggressive behavior, withincreased morbidity and mortality. The aim of this study was to investigate the impact of rejection on the incidence and presentation of SCC.
Organs donated from people infected with hepatitis C can be safely transplanted, and any transmission of the virus can be treated with antiretrovirals, new research shows.Medscape Medical News
In his book, The Checklist Manifesto: How to Get Things Right, Atul Gawande describes the origins of the checklist that involved the airline industry beginnings of the B-17 airplane.1 The test plane ’s flight ended in a deadly crash deemed due to pilot error. The B-17 was felt to be too much plane for one pilot and was abandoned as the next generation long-range bomber for the U.S. military. A persistent group of pilots developed a checklist of tasks to be performed for each phase of flight t ake-off, inflight, and landing.
ConclusionsTranscatheter LA decompression is an age-independent, effective palliation treating patients with HFpEF.
This study demonstrates that small peptide domains derived from native protein amelogenin can be utilized to construct a mineral layer on damaged human enamel in vitro. Six groups were prepared to carry out remineralization on artificially created lesions on enamel: (1) no treatment, (2) Ca2+ and PO43- only, (3) 1100 ppm fluoride (F), (4) 20 000 ppm F, (5) 1100 ppm F and peptide, and (6) peptide alone. While the 1100 ppm F sample (indicative of common F content of toothpaste for homecare) did not deliver F to the thinly deposited mineral layer, high F test sample (indicative of clinical varnish treatment) formed mainly C...
Pulmonary artery anastomosis stenosis is a rare cause of right ventricular failure after orthotopic heart transplantation. In this case report, direct ultrasound of the pulmonary artery helped diagnose stenosis at a location not visible on transesophageal echocardiography or even with standard epicardial ultrasound views. It is important to evaluate all vascular anastomoses after heart or lung transplantation because surgical revision of these lesions is facile, but if left undiagnosed, significant morbidity or mortality is likely.
TransMedica, based in Andover, Massachusetts, won FDA approval to introduce its Organ Care System (OCS) LUNG for use in standard double lung transplant procedures. The approval was based on the INSPIRE Trial, which the company touts as being the...